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Monoclonal antibodies have attracted much interest as agents to kill unwanted
cells fortherapeuticpurposes.Alimitation to thescopeofmAb therapy is the "foreign-
ness" ofmouse and rat antibodies which elicit an antiglobulin response with its at-
tendant problems . RecombinantDNAtechnology has made it possible to "humanize"
therapeutic mAbs (1-3), which in part should reduce this problem . However, the
maximum benefit of humanized antibodies will depend on their ability to activate
effector,mechanisms, such as complement- or cell-mediated killing.
To date, most of the available knowledge about the functions of the human iso-
types has come from studies of myeloma proteins (4-6), which in general do not
bind to identified antigens . Therefore, although the binding ofC1q in solution has
been extensively studied (7, 8), there had, until recently, been no definitive experi-
ments to compare the lytic ability ofthe human isotypes. However, such studies were
made possible by theconstruction ofamatched set ofchimeric antibodies (9). These
consist of the same mouse light chain and a heavy chain assembled from different
human constant regions each joined to the same mouse variable region, specific for
the hapten 5-iodo-4-hydroxy-3-nitrophenacetyl (NIP).' The use of identical V
regions means that the effect of isotype can be studied independently ofany effects
dueto differences in antigen specificity or affinity. The NIP hapten can be attached
to red cells and thus the whole pathway of complement activation can be studied
from Cl binding and activation through C4, C2, and C3 binding to assembly of
the membrane attack complex and cell lysis .
Among the four IgG antibodies, the IgG3 wasthemost efficient for Clqbinding,
consistent with previous findings for myeloma proteins . Suprisingly, however, the
IgGl antibody was much more efficient for cell lysis with human complement (9) .
To exploit the full potential of complement lysis in therapy, it will be important to
understand thereason for this paradox, and to use this knowledge to engineer better
antibodies .
Here we examined human IgGl, IgG2, IgG3 (including two different allotypes),
IgG4, and IgE for their abilities to activate key stages of the complement cascade,
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bridge,U.K .M . Br6ggemann is the recipient ofa special fellowship from theLeukemiaSociety of America . ' Abbreviations used in this paper . NIP, 5-iodo-4-hydroxy-3-nitrophenacetyl ; NIP-RBC, human red blood
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Clq binding, Cl binding and activation, C4 activation, and deposition ofC4 and
C3 on the cellmembrane.Anew chimeric antibody consisting of theratIgG2b con-
stant region joined to the same mouse anti-NIP V region was also included . This
is the optimum rat IgG for fixing human complement and cell lysis (10, 11) and we
have found that at least one rat IgG2b (CAMPATH-1G) (12) is very effective for
cell depletion in vivo. Thus, rat IgG2bprovides astandard againstwhichthehuman
isotypes can be compared . Weshow that the lytic abilityofthe humanIgG1 is greater
than rat IgG2b and that the critical advantage of human IgG1 over human IgG3
occurs at the stage of C4 activation .
Materials and Methods
CellHandlingMedium.
￿
Unless otherwise stated, cells were suspended andwashed in Iscove's
modified Dulbeccdsmedium, buffered with N-2-hydroxyethyl-piperazine-N'-2-ethanesulphonic
acid (Hepes), and containing 1% BSA . This will be referred to simply as medium .
Construction andPurification ofChimericAntibodies.
￿
The detailed construction of the chimeric
human antibodies has been previously described (9) . A plasmid (pSVVP) containing the
V gene of a mouse anti-NIP antibody (3) was used to insert varioushuman C genes down-
stream of theV . The plasmids were transfected into the mouse plasmacytoma J558L (13),
which secretes a 1l light chain, but expresses no heavy chain of its own . The endogeneous
light chain complements the transfected heavy chain to yield a NIP-specific antibody. A chi-
meric rat IgG2b antibody was constructed using the same plasmid and a previously isolated
rat IgG2b gene (14).The chimeric antibodies were purified from culture supernatant by affinity
chromatography on a column of NIP-caproate Sepharose as described before (9) .
Antibodies to Human Complement Components.
￿
A polyclonal sheep antiserum to human C4
was purchased from Serotec Ltd ., Oxford, UK (catalog no . AHP 032X/Y) . In specificity
checks by the manufacturer it reacted with only theC4 component . A rat IgG2amAb (clone
3) to the C3d fragment ofhuman C3 (15) was the gift ofDr. R . Harrison and Professor P
J . Lachmann (Mechanisms in Tumour Immunity Unit, MRC Centre, Cambridge, UK) .
It was purified from ascitic fluid by precipitation with ammonium sulphate to 50% satura-
tion followed by ion-exchange chromatography.
Radiolabeling ofAntibodies .
￿
Antibodies to C4 and C3d were radiolabeled by the iodogen
method (16). Between 0.5 and 1 MCi of 1251 was used to label N1 mg of total protein. La-
beled antibody was purified by gel filtration on Sephadex G75 and stored at 4°C in PBS
containing 0.05% sodium azide . Control experiments were carried out to determine the per-
centage of the labeled material that could bind to cells . A small amount of antibody (0.4
gg/ml) was incubated with a large excess ofcells on which complement components had been
activated. Under these conditions, 4% of the polyclonal anti-C4 antibody was bound to the
cells (consistent with the manufacturer's estimate of 5% specific antibody) and 65 ,70 of the
anti-CM mAb . Despite the relatively low activity of the polyclonal anti-C4 antiserum, posi-
tive binding could readily be distinguished from background binding (0.1 %) to cells incubated
without the primary sensitizing antibody (see also the legend to Table I) . The 1251-anti-C3
and 1251-anti-C4 were titrated to determine what concentrations were needed to saturate the
cell-bound C3 or C4 .
Complement Components and Sera.
￿
1251-labeled Clq and Cl were the generous gifts ofDr.
N . HughesJones and B . Gorick (M .I.TI . Unit, MRC Centre, Cambridge, UK). They were
isolated from human serum (17, 18) and labeled with 1251 by the lactoperoxidase method (19) .
Purified C1 inhibitor and C4-deficient guinea pig serum were the gifts ofDr . R . Harrison .
Serum from an individual genetically deficient inC6 was the gift ofDr .A . Orren (University
of Cape Town, South Africa) . Its hemolytic activity with respect to all other complement
components was confirmed by addition ofpurifiedC6 (a gift ofDr . A . Galvani,M .I.TI . Unit) .
This gave a similar hemolytic titer to normal serum. Normal human serum was obtained
from defibrinated blood ofhealthy volunteers . It was either used fresh or stored at -70°C .
Guinea pig serum was obtained from clotted blood . Cytotoxic antibody was removed by twoBINDON ET AL .
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cycles ofabsorption onhumanRBC, on ice, in the presence ofEDTA, followed by restoration
of Cat* to 10 mM, and the serum was stored at -70°C .
Preparation ofNIRcoupledRBC .
￿
Human group O red cells (4-6 wk since donation) were
obtained from the Blood Transfusion Service, Cambridge, UK . Red cells were washed exten-
sively with PBS and coupled with NIP-kephalin (a gift of Dr. U. Weltzien, University of
Freiburg, Federal Republic of Germany) as previously described (20) .
Complement-mediated Lysis.
￿
NIP-RBC were labeled with sodium ["Cr]chromate and
washed twice. They were resuspended in medium at 10' cells/ml and 50 Id of the suspen-
sion was added to round-bottomed microtiter plates containing 50 pl of an appropriate dilu-
tion of antibody (0-200 pg/ml) . After incubation for 10 min at room temperature, 100 pl
of a dilution ofcomplement was added . Human serum was used at a final concentration of
25%, and guinea pig serum at a final concentration of5%. The suspensions were incubated
at 37°C for 30 min, then centrifuged at 100 g for 2 min, and 100 pl ofthe supernatants were
collected for measurement of released radioactivity. Controls with no antibody were used
to measure the spontaneous radioactivity release . The percentage specific 51Cr release was
calculated using the formula : Percent specific release = 100 x [(test - spontaneous)/(total
- spontaneous)] .
Clq Binding by Antibody-coated Cells.
￿
Antibodies andClq were centrifuged at 15,000 g for
10 min before use in order to remove any aggregates . Washed NIP-RBC (20 Al at 2-4 x
10 8 cells/ml) in PBS containing 1% BSA were incubated with saturating amounts of anti-
body (10 pl at 200 Wg/ml) then 1251-Clq (10 P1 at 10-60 gg/ml) was added . The suspension
was rotated at 37°C for 1 h, then bound and free 1251-Clq were separated by centrifuging
each reaction mixture through 150 pl of oil with density 1.028 g/ml (a mixture of four parts
di-n-butyl phthalate and one part dinonyl phthalate) in microfuge tubes . The cell pellets were
separated by clipping off the bottom of the tubes and the radioactivity in the "bound" and
"free" fractions was determined. Specific binding of Clq was determined by subtraction of
the amount nonspecifically bound in the absence of antibody (<I%) .
CI Activation by Antibody-coated Cells.
￿
This was also measured using 1251-labeled material,
but electrophoretic analysis was necessary to determine the amounts ofthe three subcompo-
nents bound and their state ofactivation . Antibody (50 pl at 250 pg/ml) was added to a sus-
pension ofNIP-RBC in medium (150 pl at 2-4 x 108/ml) and allowed to bind at 37°C. After
10 min, 50 pl of 1251-Cl (35-80 pg/ml) was added, mixed thoroughly, and immediately the
first sample (50 pl) was removed and placed on ice to stop the activation reaction . In some
experiments, purified Cl inhibitor (10 pl at 400 pg/ml) was added to the reaction mix before
addition of Cl (80 gg/ml). The incubation was continued at 37°C and other samples were
removed at various times . All subsequent procedures were carried out on ice to prevent fur-
ther activation . Each sample was centrifuged, and the supernatant was removed . The cells
were then lysed by the addition of 100 pl of one-tenth strength medium (diluted in water),
and the membranes were pelleted by centrifugation at 15,000 g for 10 min . The supernatant
was removed, and the membranes were resuspended and analysed by SDS-PAGE on a 12%
gel under reducing conditions, followed by autoradiography. Activation ofOr and Cls in-
volves proteolytic cleavage of the 83-kD precursors to 56-kD and 27-kD fragments (Fig . 3) .
These individual bands were cut out of gels and their radioactivity was measured to deter-
mine theamount of Clr and Cls in the native (83-kD) form, and the activated (56+27-kD)
form (18) .
Cob and C3b Binding
￿
C46 and C3b binding were measured using 1251-anti-C4 and
1251-anti-C3 antibodies . NIP-RBC (20 pl and 5 x 10'-108/ml in medium) were mixed with
10 pl ofantibody (200 pg/ml), and 10 pl ofC6-deficient serum was added . C6-deficient serum
was used so that the cells would not be lysed . The suspension was incubated at 37"C for
30 min then the cells were washed twice and 40 pl of a saturating concentration of 1251-anti-
C3 or 1251-anti-C4 was added . The mixture was incubated for 30 min at room temperature
and then bound and free radiolabel were separated by centrifuging each reaction mixture
through oil as above . In some experiments the cells were washed a further three times and
incubated in medium with or without 0 .1 mM NIP-caproic acid for 10 min on ice before
centrifugation through oil . Thismade it possible to measure whether C4b orC3b were bound
to the cells or the antibody, since control experiments showed that the anti-NIP antibodie ;
could be eluted by this treatment (Table II) .130
C4 Activation.
￿
Activation ofC4 in the fluid phase by cell-bound Cls was measured by its
ability to complete a hemolytic assay consisting of sensitized erthyrocytes plus C4-deficient
serum . The assay was carried out in two stages . First, NIP-RBC (200 111 at 2 x 109/ml in
medium) were mixed with 50 111 ofC6-deficient serum on ice and 12-111 aliquots were mixed
with 4 p1 of antibody (200 gg/ml) . The samples were incubated at 37°C for various times
to allow complement activation to occur. Activation was stopped by addition of 300 111 ice-
cold medium and the cells were pelleted by centrifugation (3,000 g for 5 min) at 4°C . In
the second stage the supernatants were assayed for residual C4 hemolytic activity. Sheep
erythrocytes sensitized with an IgM anti-Forssmann antibody were labeled with 5'Cr as
above, then aliquots (50 pl, 10' cells/ml) were added to serial dilutions (50 11l) of the test su-
pernatants in microtiter trays. The reaction was completed with 100111 ofC4-deficient guinea
pig serum (diluted 1 :10 with medium) and incubated for 45 min at 37 °C . Released radioac-
tivity was measured and the dilution of test supernatant that gave half-maximal lysis was
calculated by nonlinear regression analysis .
Results
Complement-mediatedHemolysis.
￿
Lysis ofNIRRBC was measured using both human
and guinea pig complement . With human complement (Fig . 1 a) the human IgGI
was much.more efficient than any other isotype. Some lysis was seen with human
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￿
Complement-medi-
ated lysis of NIP-RBC sensi-
tized with different chimeric
anti-NIP antibodies. Lysis was
measured by a "Cr-release
assay using either autologous
human complement at a final
concentration of25% (a) or ab-
sorbed guinea pig complement
at a final concentration of5% (b).BINDON ET AL.
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FIGURE 2 . Scatchard plot of
binding of Clq to NIP-RBC
sensitized with different chi-
meric anti-NIP antibodies .
NIP-RBC were sensitized with
saturating amounts ofanti-NIP
antibodies then incubatedwith 1251-Clq . The amount of Clq
bound and free was measured
after centrifuging the cells
through oil .
IgG3 antibodies, but their titers were 100-500-fold less than that of the IgGI anti-
body. The ratIgG2bwasintermediate betweenthe IgG1 and IgG3 antibodies . Human
IgG2, IgG4, and IgE antibodies were ineffective .
With guinea pig complement the same hierarchy was obtained but all antibodies
that were previously found to be lytic showed greater efficiency. Heterologous com-
plement is generally more efficient for lysis as species-specific cell-membranefactors
inhibit complement activation on the homologous cell membrane (21-26) . Under
the more sensitive conditions provided by the use ofheterologous complement, lysis
could be obtained with the IgG2 antibody, and to a lesser extent by the IgG4, al-
though the IgE remained nonlytic .
C1qBinding .
￿
A systematic studyofvarious stages ofthecomplement cascade was
undertaken,beginning with the firstcomponent ofthe classical complement pathway,
C1q, in order to identify the component that determines the greater lytic efficiency
FIGURE 3 . Time course of
bindingand activation ofCI on
NIP-RBC sensitized with dif-
ferent chimeric antibodies . NIP-
RBC were sensitized with sat-
urating amounts of anti-NIP
antibodies andincubated with
1251-Cl. Samples were analyzed
on a 12% SDS-polyacrylamide
gel to determine the fraction
of the various subcomponents
boundand the rateat which na-
tive (83 kD) Clr and Cls was
cleaved to the56-kDand27-kD
fragments.132
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Effect of Cl inhibitor on activation of
C1 . NIP-RBC were sensitized with IgG1 (") or
ISGG3m(g) (0) antibodies and incubated with
15I-Cl in the presence or absence of Cl inhibitor.
Samples were analyzed on a polyacrylamide gel as
in Fig. 3 . The summed radioactivity in the 56-kD
and 27-kD fragments is plotted as ameasure ofacti-
vated C1 .
ofthe IgG1 . Binding of 1251-Clq was determined over a range ofClq concentrations
and a Scatchard analysis (27) was performed (Fig . 2) . This allows estimation of the
functional affinity constantsofbinding (indicated by the gradient ofthestraight line
plot), as well as the number ofC1q binding sites per cell (which is the intercept on
the x axis) . The IgG3 antibodies appeared to provide more C1q binding sites per
cell (-10,200 forthe IgG.G3m[g] and 8,900 forthe IgG.G3m[b]), than did theIgG1
antibody (-7,600) . The rat IgG2bwas intermediate (-8,500) . However, the affinity
ofClq binding (1.3-1 .6 x 10s/M) was very similar for each antibody. In other ex-
periments using a different batch ofNIRRBC (not shown) similar results were ob-
tained, but the IgG.G3m(g) antibody then gave -14,500 Clq binding sites per cell
andthe IgG1 gave only 8,300 C1q sites . In all cases, Clq bindingby the IgG2, IgG4,
and IgE antibodies was undetectable . The amount of Clq bound, although con-
tributory, was clearly an insufficient explanation for the degree of lysis seen .
CI Binding andActioation .
￿
TheIgG1 andIgG3 antibodies werecompared fortheir
ability to bind Cl and activate Or and Cls by cleavage of the 83-kD precursors to
56-kDand27-kD fragments (Fig. 3). Again, theIgG3 antibodies gavemoreC1 binding
than the IgG1 . Quantitative analysis (by measurement of radioactivity in bands cut
out of the gels) showed that both IgG3 antibodies bound about twice as much C1
as did theIgG1 antibody. In each case nearly all of thebound Cl wasactivated within
10 min. Therefore, the superior lytic efficiency of the IgG1 antibody could not be
explained by its ability to bind or activate Cl .
It was possible that Cl activation in whole serum would be different because of
the presence of C1 inhibitor, which might be able to gain better access to Cl bound
to IgG3 due to the unusually long hinge of that antibody. Therefore, a similar ex-
periment was carried out to measure C1 binding and activation in the presence of
Cl inhibitor . (The molar ratio of C1 inhibitor to Cl was adjusted to be about the
same as that in normal serum.) For both IgG1 and IgG3 antibodies the extent of
activation was reduced (Fig. 4) . However, even in the presence ofC1 inhibitor the
IgG3 antibody still gave more activated Cl than the IgGI did . No additional bands
were detected on the gel corresponding to acovalent complex ofC1 and Cl inhibitor
(-135 kD) .
C4andC3 Fixation .
￿
After activation of Cl, the next step in the classical comple-
ment pathway is the activation of C4 after proteolytic cleavage by Cls. The major
fragment, C4b, canattach to anearby acceptor molecule throughacovalent thiolesterBINDON ET AL.
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TABLE I
Amount of C4b and- C3b Bound to NIP-RBC Sensitized
with Different Antibodies
Binding of C4b and C3b was measured using 1211-anti-C4 and 1251-anti-C3.
The bound radioactivity was measured after separation of the cells from free la-
beled antibody by centrifugation through oil. The results are means ofduplicate
samples from a representative experiment. The background radioactivity ofcells
incubated without sensitizing antibody has been subtracted from each sample
(289 cpm for C4b and 583 cpm for C3b).
bond. The amount of C4b fixed on the cell surface was measured using 1151-anti-
C4 antibody. The relative amount of C4 bound by various isotypes followed a quite
different hierarchy from that observed forCl binding(Table I). The IgG1 antibody
caused considerably more C4bbinding than did either ofthe IgG3 antibodies, while
the rat IgG2b antibody was intermediate between these two. No C4b binding was
detected with IgG2, IgG4, or IgE antibodies. The hierarchy for C4b binding cor-
related well with the lysis results.
C4b fixed on the cell surface interacts with C2 to form the classical pathway C3
convertase (C4bC2b). This in turn cleaves C3 to C3b, allowing its fixation on the
cell membrane through a covalent thiolester bond in asimilarwayto C4b. C3bbinding
was measured using an mAbto C3. The amount of C3b bound correlated well with
the degree of lysis (Table I). The order of efficiency forboth C4b and C3b binding
was human IgG1 > rat IgG2b >human IgG.G3m(b) > human IgG.G3m(g). These
results were also confirmed using C6-deficient serum trace labeled with 1251-C3 to
measure C3b binding direct (data not shown).
Thus, the major difference between human IgG1 and IgG3 antibodies involved
a stage between the activation of Cl, and the fixation ofC4b on the cell membrane.
To exclude possible artefacts that could arise if, for example, some fraction of the
antibodies were inactive, we studied the binding of Clq, Cl, C4b, C3b, and lysis
simultaneously over a range of antibody concentrations (Fig. 5). Only one IgG3
(IgG.G3m[g]) was used as they both appeared similar for Cl binding (Fig. 2) and
C4b binding (Table 1). Over the whole range of antibody concentrations, the ratio
of C4b/C1 molecules bound was -10-12 times greater for the IgGI antibody com-
pared with the IgG3 antibody (Fig. 5). Likewise for the ratio of C3b/C1 molecules
where the difference was, if anything, slightly greater.
CA andC4bBind to the CellMembrane.
￿
Some studieshave suggestedthat both C4b
and C3b bind efficiently to antibody molecules (28-31). We therefore investigated
whetherC4b and C3b attached to the antibody or to the cell membrane. To do this,
Chimeric
anti-NIP antibody C4b bound C3b bound
cpm cpm
Human IgG1 2,860 8,670
Human IgG2 0 75
Human IgG.G3m(b) 1,190 4,419
Human IgG.G3m(g) 926 3,657
Human IgG4 0 0
Human IgE 0 113
Rat IgG2b 1,850 9,937134
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￿
Dependence ofC1q
binding, C1 binding, C4b bind-
ing, C3b binding, and lysison
concentration of the sensitiz-
ing antibody. NIP-RBC were
sensitized with IgG1 (") or
IgG.G3m(g)(0) antibodies at
a range ofconcentrations .Com-
plement activation andcell lysis
were measured as before.When
the specific activity ofthe radio-
labeled reagentswasknown, the
results were calculated in terms
of molecules bound per cell,
otherwise theywererecorded as
measured cpm.
antibody was eluted from the cell surface undermild conditions using soluble hapten.
The efficacy of this procedure was demonstrated using 1211-labeled IgG1 or
IgG.G3m(g) bound to NIRRBC . To one sample, NIP-caproic acid was added, and
this was compared with a control sample of antibody-coated NIRRBC to which no
free hapten was added . In the presence of added NIPcaproic acid only 3-6% of
the antibody remained bound to the cell surface, while in the control samples, >90%
still remained bound after 45 min (Table II) . Elution of antibody occurred equally
wellwhen cells hadbeen incubated in C6-deficientserumto allowactivation ofcom-
plement components C1 to C5 (data not shown) .
Usingthis elution technique we tested whetherremoval ofthe antibody also caused
removalofboundC4b and C3b, orwhether they remained attached to the red cells .BINDON ET AL.
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TABLE II
Elution of Anti-NIP Antibodies from the Cell Surface by NIP-Caproic Acid
NIP-RBC were labeled with 1251-anti-NIP antibodies then incubated with or
without NIP-caproic acid. The percentage of radioactivity that remained cell
bound was measured after the cells had been separated from released antibody
by centrifugation through oil.
The IgGI and IgG3 anti-NIP antibodies were incubated with NIRRBC in the pres-
ence of C6-deficient serum, and deposition of C4b or C3b was assayed with
"'I-anti-C4 or 1251-anti-C3 as before. Addition of NIP-caproic acid had very little
effect on the bound anti-C4 and anti-C3 antibody (Table III). This suggests that
most, if not all, of the C4b and C3b were fixed on the cell surface rather than on
the antibody molecule, for both IgGI and IgG3 antibodies.
C4 Activation.
￿
Having shown that C4bwasnot efficiently deposited on the mem-
branes when cells were sensitized with IgG3, we measured the extent of C4 activa-
tion in the presence of IgGI or IgG3. To do this we assayed residual C4 activity
in the supernatant and in order to obtain a measurable decrease it was necessary
to use a higher cell concentrationthan in theprevious experiments. The results(Fig.
6) showed that the rate of C4 activation with IgG3 was much less than that seen
with IgGI, showingthat the poor lyticactivity of IgG3 waslikely to be dueto inefficient
activation of C4 rather than inefficient deposition of activatedC4 on thecell membrane.
TABLE III
Effect of NIP-Caproic Acid on C4b and Cab Binding
NIP-RBC sensitized with IgG1 or IgG3 anti-NIP antibodies were incubated with C6-deficient
serum then washed and incubated with "'I-anti-C4 or 1251-anti-C3. The cells were washed
again and incubated with or without NIP-caproic acid to elute the sensitizing antibody. The
percentage of C4b or C3b attached to the cells was calculated from the bound and free radioac-
tivity measured after centrifuging the cells through oil.
Antibody
isotype
NIP-caproic acid
Bound Free
cpm cpm
added
Percent
bound
Bound
cpm
Control
Free
cpm
Percent
bound
C4b binding
IgGI 22,000 770 97 22,800 720 97
IgG.G3m(b) 11,700 650 95 12,200 540 96
IgG.G3m(g) 7,400 380 95 7,800 350 96
C3b binding
IgGl 9,000 220 98 9,700 210 98
IgG.G3m(b) 2,500 210 92 2,900 140 96
IgG.G3m(g) 1,500 130 92 1,600 50 97
Isotype of
1251-labeled antibody remaining
labeled anti-
NIP antibody
NIP-caproic
acid (0.1 mM) 5 min
bound to the
20 min
cell surface
40 min 80 min
IgGl + 5 6 5 4
IgGl - 94 90 94 86
IgG.G3m(g) + 3 4 4 4
IgG.G3m(g) - 95 94 96 92136
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Rate ofactivation ofC4. NIP-RBCwere sensitized with
IgGl (0) or IgG.G3m(g) (0) antibodies or medium alone(O) and
incubated with C6-deficient serum forvarious times. Samples ofthe
supernatant were assayed forresidual C4 activity bytitration in ahemo-
lytic assay.
Discussion
In view of current efforts to obtain "humanized" antibodies for therapy, it is im-
portantto establish the range ofeffector functionsoftheindividual human isotypes.
Ideally, one would like to optimize all available effector mechanisms for clearance
ofcells in vivo. Different studies have demonstrated the importance both ofcellular
mechanisms (32, 33) and ofcomplement fixation (34, 35). Our observations that
theIgG1 isotypeisthemost effectiveforbothcomplement lysisandantibody-dependent
cell-mediated killing (9) suggest that this subclass is likely to be the one ofchoice.
The superiority of IgG1 for lysis was demonstrated with both human and with
guinea pig complement, although the absolute levels oflysis were greater with the
heterologous complement. Complement that ishomologous withrespect to thetarget
cells is almost invariably lessefficient for lysis(21, 22), dueto cell membrane factors
such as decay-accelerating factor and the homologous restriction factor which in-
hibit complement activation in a species-restricted manner (23-26). However, the
fully homologous system is the only one relevant to therapy, so in the studies ofin-
dividual stages of the complement cascade, we used human components and sera.
When the efficiency for lysis was measured by antibody titer, the hierarchy be-
tween isotypes (human IgG1 > rat IgG2b > human IgG3 > human IgG2 > human
IgG4 > human IgE) was identical for different complement sources. As the various
isotypes had the sameVregion and presumably identical binding affinity, the same
numberofantibody molecules should have been bound at anyparticularinput con-
centration. Therefore, ahigher antibody titerimplies that fewerantibody molecules
bound per cell are required to give lysis. Conditions that reduce the sensitivity of
the target cells to lysiswill require ahigher antibody concentration to give the same
amount oflysis. This was illustrated by the comparison ofhomologous complement
(Fig. 1 a) with heterologous complement (Fig. 1 b). In a therapeutic situation we
might expect further reductions in the sensitivity of the cells to lysis, first because
the target antigen may be at lower density, and second, because nucleated cells re-
quire more complement channels for lysis. Therefore, the 100-500-fold differenceIgG1
IgG3
10 mn
IgG2
IgG4
BINDON ET AL.
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FIGURE 7.
￿
Structure of the human IgG isotypes, redrawn
from reference 52 with permission.
in titers between the IgGI and IgG3 antibodies will be critical and possibly only
the IgG1 antibody will give any lysis at all.
To investigate why IgG1 was so lytic we studied various stages ofthe complement
activation sequence. C1q binding was only detected with IgG3, IgG1, and rat IgG2b
antibodies, but not with IgG2, IgG4, or IgE antibodies. The hierarchy agreed well
with previous results for human myeloma proteins. Affinity constants for binding
of Clq to monomeric human IgG in solution are as follows: IgG3 (Ka = 2.9 x
104/M), IgGI (Ka = 1.2 x 104/M), IgG2 (Ka = 0.64 x 104/M), IgG4 (Ka = 0.44
x 104/M) (8). We failed to detect Clq binding by IgG2 and IgG4 antibodies, but
it is likely that some binding that was too weak to detect in the assay used did take
place, which would account for the hemolysis obtained with guinea pig complement.
Scatchard analysis showed that the IgG.G3m(g), IgG.G3m(b), IgGI, and rat IgG2b
antibodies all had similar functional affinity constants for C1q binding of -1.5 x
108/M. This was comparable with previous estimates of functional affinity constants
for bivalent binding ofClq (36), and as expected, several orders ofmagnitude higher
than the values for monomeric binding. Differences were observed in the numbers
of Clq binding sites per cell; for example, the IgG.G3m(g) appeared to provide
-1.35-1.7 times as many binding sites as the IgG1 antibody. Despite considerable
information indicating differences in the C1q binding ability of various isotypes in
the case of the human (8), mouse (37), and rat (38, 39), the reasons for these differ-
ences are still not entirely clear. Clq binds to the CH2 domain of the antibody Fc
region, and three different sites have been proposed (40-42). However, the primary
sequence in each is very similar between the various isotypes. Some have suggested
that differences between isotypes arise due to the flexibility of the antibody mole-
cule, and depend on the length of the hinge region (43-44). Human IgG3 has an
extraordinarily long hinge compared with the other isotypes (Fig. 7). This could
result in more C1q binding sites on the cell surface as there would be more opportu-
nities for two antibody Fc regions to come into appropriate proximity.138
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Previous observations have suggested that C1q and C1 binding may be indepen-
dently regulated (45) and that bound C1 is not necessarily activated (19, 46). It was
therefore possible that a difference at this level might explain the paradox between
Clq binding and hemolysis. In fact, the superiority of the IgG3 antibodies in C1q
binding was even more marked when the binding ofwhole C1 was studied (Fig. 3).
When the binding of C4 and C3 were measured, a very different picture was ob-
tained (Table 1, Fig. 5) and nowtheisotypehierarchy was the same as in hemolysis.
This suggestedthat thecritical difference betweenIgG1 and IgG3 occurred between
the stages of activated C1 and the fixation of C4 on the cell surface. After the en-
zymatic cleavage of C4 and C3, an activated molecule is produced, where the in-
ternal thiolester hasthe capacity to form acovalent bond with an acceptor nucleophile
(hydroxyl or amino group) on the cell membrane. However, the activated molecule
has a half-life of only about 25-30 ps in solution (47, 48) because the thiolester is
rapidlyhydrolyzed. Furthermore, notallhydroxyl or amino groups areequally efficient
as acceptor molecules (49) and only a fraction of C4b and C3b is deposited at the
complement activation site. The proportion that binds will depend on the precise
nature and vicinity of acceptor groups that are available. One hypothesis to explain
why IgG1 gave more C4b binding was that the IgG1 constant region might have
been a particularly good acceptor. Studies using immune complexes or antibody-
coated bacteria have shown that antibody can be a good acceptor of both Cob (28)
andC3b (29-31). In contrast, experimentsusingred cells coupledwith methotrexate
suggested that both C4b and C3b were bound to the cell surface rather than to the
antibody molecule (50, 51). Ourresults areconsistent with theselatter findings. The
ability of the chimeric antibodies to provide an acceptor site could not account for
differences in C4 fixation, as most oftheC4b and C3b were bound to the cell mem-
brane (Table III).
Theaverage distance that C4bcandiffuseduring thehalf-lifeofthenascentthiolester
bond is -6 nm, rather less than the relaxed length of the hinge region (9 nm) in
IgG3 (Fig. 7) (52). Therefore, it was conceivable that C4 was activated but did not
reach the cell surface before decaying. This explanation was ruled out by measure-
ment of residual (unactivated)C4 in the cell supernatants (Fig. 6). It appeared that
Cls activated via IgG3 was very inefficient at activation of C4.
Perhaps the unusual size of the IgG3 molecule may allow access of Cl inhibitor
to the activated Cl; Cl inhibitor is a large serum protein, which can usually only
bind to C1 in solution. Thus, C1 inhibitor may attach to the activated Cls and block
C4 activation. We didnot see theC1-inhibitor-Clr complex at -135 kD on the SDS
gel, but Cl-inhibitor-Cls would have been invisible because the 27-kD fragment of
Cls does not contain an iodination site. The other possibility is that binding of C4
to theC1 complex is favored by IgG1 but notby IgG3. We could imagineanoncova-
lent binding site forC4 on IgG1, but not on IgG3, which stabilizes the interaction.
Alternatively, perhaps the long flexible hinge of IgG3 allows proportionally more
three-headed binding of C1, preventing C4 from gaining access to the active site.
Thesetheories could be distinguished by usingchimeric antibodies with appropriate
genetic changes.
So farthese results hold forthe model system of hapten-coated erythrocytes. This
was convenient forourexperimentsbut notof greatphysiological importance. How-
ever, recent studieswith an analogousmatched setof chimeric humanmAbs specificBINDON ET AL.
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for the humanlymphocyte antigen CAMPATH-1 have shown the same paradoxical
hierarchy of complement lysis when lymphocytes are used as targets (53), and so
IgGl does seem to be superior for cell lysis in general. In different circumstances
it is possible that IgG3 has a more important role in complement fixation, for ex-
ample in clearance of immune aggregates or of bacteria or viruses. At present we
cannot say whether the poor C4 fixing ability would apply in those situations.
An important conclusion from the work presented here is that antibody isotype
can influence complement-activating function at alevel other than the binding of
Clq, namely at the level of C4 activation. Future efforts to improve the lytic ability
ofmAbs by genetic engineeringwill need to allowfortheeffect of antibody structure
on this stage in the complement cascade. By appropriate genetic manipulation it
might be possible to combine the greaterC1-activating ability of the IgG3 with the
greater C4 fixing capacity of IgG1 to produce an antibody with even better lytic
capability than any of the native isotypes.
Summary
Humanized antibodies are likely to have a major role in therapy and it is impor-
tant to define theirinteraction with physiological effectors. By comparing a matched
series of chimeric human mAbs we found that IgG1 was most efficient in comple-
ment lysis, although IgG3 bound more Clq. To resolve this paradox we compared
the ability of human IgGl, IgG2, IgG3, IgG4, and IgE and rat IgG2b to cause Clq
binding, Cl binding and activation, C4 activation, Cob binding, and C3b binding.
Rat IgG2bwas included because this isotype has already successfully been used for
therapy. Human IgG1 was less efficient than IgG3 and fixing Clq and C1 on the
cell surface, but the number of C4 molecules bound per Cl was 10-fold greater for
IgG1 than for IgG3 . This difference, amplified through later stages of the comple-
ment cascade, can account for the superiority of IgGl for cell lysis. The efficiency
of IgG1 in fixing C4 was not dueto afavored bindingsite on theantibody molecule,
since virtually all of the bound C4b was attached to the cells. Rather, it appeared
that the activation of C4 by Cls was greatly favored by IgG1 compared with IgG3.
It should be possible to combine the optimalproperties of IgGl and IgG3 antibodies
to produce an improved therapeutic reagent.
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